(Total Views: 626)
Posted On: 11/19/2021 8:08:38 AM
Post# of 154883
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that its research paper entitled “CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody Leronlimab” has been accepted by Frontiers in Immunology, a leading journal in its field publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
The article can be found here: http://journal.frontiersin.org/article/10.338...;id=794638
Importantly, the results of the study outlined in the research paper:
Establish two CCR5 receptor occupancy calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans;
Demonstrate that CCR5+CD4+ T cell levels temporarily increase with leronlimab treatment; and
Facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.
“We are thrilled that the Frontiers in Immunology journal has published this important paper to inform further the scientific community of these exciting developments with leronlimab,” said CytoDyn’s Chief Medical Officer, Scott A. Kelly M.D. “We will relentlessly pursue the various indications for leronlimab to realize its full therapeutic potential. Our continued work on the mechanism of action of leronlimab continues to lay the foundation for more exciting opportunities of leronlimab for patients and our shareholders.”
VANCOUVER, Wash.--(BUSINESS WIRE)-- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that its research paper entitled “CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody Leronlimab” has been accepted by Frontiers in Immunology, a leading journal in its field publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
The article can be found here: http://journal.frontiersin.org/article/10.338...;id=794638
Importantly, the results of the study outlined in the research paper:
Establish two CCR5 receptor occupancy calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans;
Demonstrate that CCR5+CD4+ T cell levels temporarily increase with leronlimab treatment; and
Facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.
“We are thrilled that the Frontiers in Immunology journal has published this important paper to inform further the scientific community of these exciting developments with leronlimab,” said CytoDyn’s Chief Medical Officer, Scott A. Kelly M.D. “We will relentlessly pursue the various indications for leronlimab to realize its full therapeutic potential. Our continued work on the mechanism of action of leronlimab continues to lay the foundation for more exciting opportunities of leronlimab for patients and our shareholders.”
(10)
(0)
My comments are just my opinions and should NOT be taken as investment advice.
